PURPOSE: The aims of this study are to examine the validity of diagnostic codes for psoriatic arthritis in The Health Improvement Network (THIN) and to examine the agreement between General Practitioner (GP) report and prescription records for disease modifying antirheumatic drugs (DMARDs). METHODS: Questionnaires were sent to the GPs of 100 randomly selected patients with at least one medical record code for psoriatic arthritis. The positive predictive value (PPV) for a GP confirmed diagnosis was calculated, and alternative algorithms were examined to determine which method resulted in the highest PPV. RESULTS: The PPV for a single code for psoriatic arthritis was 85% (95%CI: 75.8-91.7%). Adding a prescription for a DMARD increased the PPV to 91% but with a substantial loss in sensitivity. Agreement between GPs and prescription data for use of an oral DMARD was 69%. CONCLUSIONS: The diagnosis codes for psoriatic arthritis used in THIN are valid. All prescriptions for DMARDs may not be accounted for in THIN.
PURPOSE: The aims of this study are to examine the validity of diagnostic codes for psoriatic arthritis in The Health Improvement Network (THIN) and to examine the agreement between General Practitioner (GP) report and prescription records for disease modifying antirheumatic drugs (DMARDs). METHODS: Questionnaires were sent to the GPs of 100 randomly selected patients with at least one medical record code for psoriatic arthritis. The positive predictive value (PPV) for a GP confirmed diagnosis was calculated, and alternative algorithms were examined to determine which method resulted in the highest PPV. RESULTS: The PPV for a single code for psoriatic arthritis was 85% (95%CI: 75.8-91.7%). Adding a prescription for a DMARD increased the PPV to 91% but with a substantial loss in sensitivity. Agreement between GPs and prescription data for use of an oral DMARD was 69%. CONCLUSIONS: The diagnosis codes for psoriatic arthritis used in THIN are valid. All prescriptions for DMARDs may not be accounted for in THIN.
Keywords:
database; disease modifying antirheumatic drug (DMARD); pharmacoepidemiology; psoriatic arthritis; the health improvement network; validation
Authors: N M Seminara; K Abuabara; D B Shin; S M Langan; S E Kimmel; D Margolis; A B Troxel; J M Gelfand Journal: Br J Dermatol Date: 2011-02-03 Impact factor: 9.302
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Epidemiology Date: 2007-11 Impact factor: 4.822
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: Joel M Gelfand; Dafna D Gladman; Philip J Mease; Nana Smith; David J Margolis; Tamar Nijsten; Robert S Stern; Steven R Feldman; Tara Rolstad Journal: J Am Acad Dermatol Date: 2005-10 Impact factor: 11.527
Authors: Alexis Ogdie; Neilia Kay McGill; Daniel B Shin; Junko Takeshita; Thorvardur Jon Love; Megan H Noe; Zelma C Chiesa Fuxench; Hyon K Choi; Nehal N Mehta; Joel M Gelfand Journal: Eur Heart J Date: 2018-10-14 Impact factor: 29.983
Authors: Alexis Ogdie; Lauren Harter; Daniel Shin; Joshua Baker; Junko Takeshita; Hyon K Choi; Thorvardur Jon Love; Joel M Gelfand Journal: Ann Rheum Dis Date: 2017-01-16 Impact factor: 19.103
Authors: Alexis Ogdie; YiDing Yu; Kevin Haynes; Thorvardur Jon Love; Samantha Maliha; Yihui Jiang; Andrea B Troxel; Sean Hennessy; Steven E Kimmel; David J Margolis; Hyon Choi; Nehal N Mehta; Joel M Gelfand Journal: Ann Rheum Dis Date: 2014-10-28 Impact factor: 19.103
Authors: Kashif Jafri; Christie M Bartels; Daniel Shin; Joel M Gelfand; Alexis Ogdie Journal: Arthritis Care Res (Hoboken) Date: 2016-11-28 Impact factor: 4.794